Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Hikma Pharmaceuticals plc. (OTC: HKMPY).

Full DD Report for HKMPY

You must become a subscriber to view this report.


Recent News from (OTC: HKMPY)

Hikma Demonstrates Support for US Pharmacists and Patient Safety
Activities at upcoming ASHP conference include sponsorship of important symposium advancing patient safety practices Hikma Pharmaceuticals USA Inc ., a wholly owned subsidiary of Hikma Pharmaceuticals PLC (“Hikma”) (LSE:HIK) (NASDAQ Dubai:HIK) (OTC:HKMPY), the multina...
Source: Business Wire
Date: November, 30 2018 17:36
Amarin's REDUCE-IT Trial: Something Fishy?
Introduction I hope that everyone reading this has a baseline knowledge of Amarin ( AMRN ), its sole product Vascepa, and the REDUCE-IT cardiovascular outcomes trial, or CVOT. Further, presumably everyone is aware of AMRN's recent revelation of positive topline results of REDUCE-IT, with ...
Source: SeekingAlpha
Date: November, 11 2018 09:46
Hikma Pharmaceuticals Plc. 2018 Q2 - Results - Earnings Call Slides
The following slide deck was published by Hikma Pharmaceuticals plc. in conjunction with their 2018 Q2 earnings Read more ...
Source: SeekingAlpha
Date: August, 15 2018 13:48
Longleaf Partners Shareholder Letter Q2 2018
Read more ...
Source: SeekingAlpha
Date: July, 26 2018 07:05
Hikma Acts to Ease Critical Shortage of Pain Medications Needed by US Hospitals and Their Patients
Leading Generic Pharmaceutical Company Increases Manufacturing Capacity to Produce and Release Significant Quantities of Scarce Medicines Hikma Pharmaceuticals PLC (the Hikma Group) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), the multinational generic pharmaceutical company, announce...
Source: Business Wire
Date: July, 18 2018 07:00
Longleaf Partners Shareholder Letter Q1 2018
Read more ...
Source: SeekingAlpha
Date: April, 15 2018 06:38
Propeller Health Publishes Results From a Large Public Health Study on Asthma; Successfully Reduces the Burden of Asthma in Louisville
MADISON, Wis. , April 2, 2018 /PRNewswire/ -- Today Propeller Health and peer-reviewed healthcare journal, Health Affairs , published results from a cross-sector partnership in Louisville, KY , that successfully reduced the burden of asthma. AIR Louisville , one of the largest s...
Source: PR Newswire
Date: April, 02 2018 18:11
Propeller Health Achieves ISO 13485 Medical Device Quality Certification
MADISON, Wis. , Feb. 8, 2018 /PRNewswire/ -- Propeller Health, the leading digital solution for respiratory medicine, has been awarded International Organization for Standardization (ISO) 13485:2016 certification for medical device quality management systems. Propeller's FDA-cleared ...
Source: PR Newswire
Date: February, 08 2018 07:00
Propeller Health Achieves HITRUST CSF Certification to Further Mitigate Risk in Third Party Privacy, Security and Compliance
MADISON, Wis. , Dec. 20 , 2017 /PRNewswire/ -- Propeller Health, the leading digital solution for respiratory medicine, today announced that Propeller Health System's associated infrastructure used to store, process, maintain, and transmit customer ePHI has earned Certified status f...
Source: PR Newswire
Date: December, 20 2017 18:22
Propeller Health and Express Scripts Partnership Offers Innovative Digital Respiratory Care to Improve Health for People with Asthma or COPD
MADISON, Wis. and ST. LOUIS , Nov. 16, 2017 /PRNewswire/ -- Today, Propeller Health and Express Scripts (NASDAQ: ESRX) announced a strategic partnership to provide Propeller's FDA-cleared digital solution to Express Scripts members using inhaler sensors and a mobile app to manage asthma...
Source: PR Newswire
Date: November, 16 2017 06:00

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-14N/A44.84N/AN/A0
2018-12-13N/A44.84N/AN/A0
2018-12-12N/A44.84N/AN/A0
2018-12-11N/A44.84N/AN/A0
2018-12-10N/A44.84N/AN/A11

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-10-052001,74411.4679Cover
2018-10-03442,0262.1718Cover
2018-09-271,5001,500100.0000Short
2018-09-1910020050.0000Short
2018-09-1314924959.8394Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on HKMPY.


About Hikma Pharmaceuticals plc. (OTC: HKMPY)

Logo for Hikma Pharmaceuticals plc. (OTC: HKMPY)

Not available

 

Contact Information

 

 

Current Management

  • Said Darwazah / CEO
  • Bassam Kanaan / EVP, CFO
  • Samih Darwazah / Chairman

Current Share Structure

  • Market Cap: $2,436,097,500 - 03/13/2018
  • Issue and Outstanding: 194,887,800 - 07/21/2011

 



Daily Technical Chart for (OTC: HKMPY)

Daily Technical Chart for (OTC: HKMPY)


Stay tuned for daily updates and more on (OTC: HKMPY)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: HKMPY)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in HKMPY is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of HKMPY and does not buy, sell, or trade any shares of HKMPY. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/